Xigris Purple Book BLA 125029

BLA number
125029
Proprietary names
Xigris
Proper names
drotrecogin alfa
Applicant
Eli Lilly and Company
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Xigrisdrotrecogin alfa351(a)5MGInjectionIntravenousSingle-Dose VialDiscVoluntarily Revoked2001-11-21
002Xigrisdrotrecogin alfa351(a)20MGInjectionIntravenousSingle-Dose VialDiscVoluntarily Revoked2001-11-21

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-03-01U001Xigris351(a)DiscEli Lilly and Company
2021-03-01U002Xigris351(a)DiscEli Lilly and Company
2020-09-01U001Xigris351(a)DiscEli Lilly and Company
2020-09-01U002Xigris351(a)DiscEli Lilly and Company
2020-05-01R001Xigris351(a)DiscEli Lilly and Company
2020-05-01R002Xigris351(a)DiscEli Lilly and Company

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Xigris351(a)DiscVoluntarily Revoked2001-11-21
2020-08-01002Xigris351(a)DiscVoluntarily Revoked2001-11-21
2020-05-01001Xigris351(a)DiscVoluntarily Revoked
2020-05-01002Xigris351(a)DiscVoluntarily Revoked